EMA committee recommends market withdrawal of obesity drug
Obesity drug amfepramone is not used as it was intended and can cause serious side effects, which is why the European Medicines Agency’s risk assessment committee recommends market authorizations be withdrawn.
by christian bundgaard, translated by daniel pedersen
Studies from both Denmark and Germany have made the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommend that obesity drugs containing amfepramone be withdrawn from the market, the committee reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly squares up to Novo Nordisk on obesity market
For subscribers
Wegovy celebrates first birthday with subdued cheers
For subscribers
